References
- Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024–1039.
- Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858–871.
- Kaltenboeck A, Bach PB. Value-based pricing for drugs: theme and variations. JAMA. 2018;319(21):2165–2166.
- Emanuel EJ, Zhang C, Glickman A, et al. Drug reimbursement regulation in 6 peer countries. JAMA Intern Med. 2020;180(11):1510–1517.
- Vogler S, Paris V, Ferrario A, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–321.
- Vogler S, Zimmermann N, Leopold C, et al. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Rev. 2011;4(2):69–79.
- Thornhill MH, Dayer MJ, Forde JM, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ. 2011;342(1):d2392.
- Rogers Van Katwyk S, Grimshaw JM, Nkangu M, et al. Government policy interventions to reduce human antimicrobial use: a systematic review and evidence map. PLOS Med. 2019;16(6):e1002819.
- Gong Y, Yang C, Yin X, et al. The effect of essential medicines programme on rational use of medicines in China. Health Policy Plan. 2016;31(1):21–27.
- Association JPM. Health insurance programs and drug pricing in Japan. Pharmaceutical Regulations in Japan; 2020 [cited 2022 Jan 7]. Available from: https://www.jpma.or.jp/english/about/parj/eki4g6000000784o-att/2020e_ch06.pdf
- Japanese Ministry of Health, Labour, and Welfare. Annual trends in national health care expenditures; 2021 [cited 2021 Jul 14]. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/18/dl/toukei.pdf
- Japanese Ministry of Health, Labour, and Welfare. Annual trends in drug costs and estimated deviation rates; 2019 [cited 2021 Jul 23]. Available from: https://www.mhlw.go.jp/content/12404000/000376813.pdf
- Japanese Ministry of Health, Labour, and Welfare. About rule of NHI price calculation method in FY 2020; 2021 [cited 2021 Jul 27]. Available from: https://www.mhlw.go.jp/web/t_doc?dataId=00tc5663&dataType=1&pageNo=1
- Kamae I, Thwaites R, Hamada A, et al. Health technology assessment in Japan: a work in progress. J Med Econ. 2020;23(4):317–322.
- Lin PJ, Cohen JT, Neumann PJ. Preparing the health-care system to pay for new Alzheimer's drugs. Alzheimers Dement. 2020;16(11):1568–1570.
- Braendstrup P, Levine BL, Ruella M. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy. 2020;22(2):57–69.
- Crosson FJ, Covinsky K, Redberg RF. Medicare and the shocking US food and drug administration approval of aducanumab: crisis or opportunity? JAMA Intern Med. 2021;181(10):1278–1280.
- Senior M. Rollout of high-priced cell and gene therapies forces payer rethink. Nat Biotechnol. 2018;36(4):291–293.
- Japanese Ministry of Health, Labour, and Welfare. Central Social Insurance Medical Council. [cited 2020 Jul 3]. Available from: https://www.mhlw.go.jp/stf/shingi/shingi-chuo_128154.html
- Pharmaceuticals and Medical Devices Agency (PMDA). The list of newly approval drugs [cited 2021 Apr 20]. Available from: https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0010.html
- Japanese Ministry of Health, Labour, and Welfare. The fifth NDB open data [cited 2021 May 19]. Available from: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177221_00008.html
- Kossmeier M, Themanns M, Hatapoglu L, et al. Assessing the accuracy of sales forecasts submitted by pharmaceutical companies applying for reimbursement in Austria. Front Pharmacol. 2021;12:2072.
- Keeping S, Deslandes PN, Haines KE, et al. Estimated versus observed expenditure associated with medicines recommended by the all Wales medicines strategy group. Pharmacoecon Open. 2019;3(3):343–350.